SCHEDULE: Opaleye Management Discloses 8.65% Stake in Q32 Bio

Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, reported a passive beneficial ownership of 8.65% of Q32 Bio Inc.'s common stock.

Summary

• Opaleye Management Inc., Opaleye, L.P., and James Silverman collectively reported beneficial ownership of 1,256,228 shares of Q32 Bio Inc. common stock.
• This represents 8.65% of the total outstanding common shares of Q32 Bio Inc.
• The percentage is based on 14,524,726 common shares outstanding as of February 17, 2026, as reported by Q32 Bio Inc. in its 424B5 Prospectus.
• The reporting persons share both voting and dispositive power over all 1,256,228 shares.
• The shares were not acquired for the purpose of changing or influencing control of Q32 Bio Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant passive stake by an institutional investor can signal confidence in Q32 Bio Inc.'s long-term value, though it doesn't imply active engagement in management or strategy.

Positives

• A significant institutional investor, Opaleye Management Inc., has taken a substantial passive stake in Q32 Bio Inc., potentially signaling confidence in the company's long-term prospects.

Negatives

• No specific negative information is contained within this Schedule 13G filing.

Risks

• No specific risks related to Q32 Bio Inc. are detailed in this ownership disclosure filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Q32 Bio Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• James Silverman certified that the securities were not acquired and are not held for the purpose of changing or influencing the control of Q32 Bio Inc.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership changes, which can sometimes precede increased market attention or validate a company's investment thesis within its sector. For Q32 Bio Inc., a biotechnology company, a substantial passive stake from an investment manager like Opaleye Management could be viewed positively by the market, especially if Opaleye has a track record of successful investments in the biotech space.

Comparison to Industry Standards

• This filing represents a standard Schedule 13G disclosure of a passive stake exceeding 5% by an institutional investor, aligning with regulatory transparency requirements.
• No specific comparable companies, projects, or results are detailed within this ownership disclosure filing to assess against global benchmarks, as it focuses solely on beneficial ownership.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder and potential positive sentiment due to a large passive investment.
• Regulatory Authorities: The filing ensures compliance with SEC disclosure requirements for beneficial ownership exceeding 5%.

Next Steps

• No specific future actions or milestones are mentioned in this ownership disclosure filing.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Opaleye Management Inc., has taken an 8.65% passive stake in Q32 Bio Inc. While this signals potential confidence in the company's value, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It's a disclosure of ownership, suggesting investors should 'hold' and monitor future developments and Q32 Bio Inc.'s operational performance.

Keywords

Q32 Bio Inc., Opaleye Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Stake, Biotechnology